JP2022545765A5 - - Google Patents

Info

Publication number
JP2022545765A5
JP2022545765A5 JP2021577965A JP2021577965A JP2022545765A5 JP 2022545765 A5 JP2022545765 A5 JP 2022545765A5 JP 2021577965 A JP2021577965 A JP 2021577965A JP 2021577965 A JP2021577965 A JP 2021577965A JP 2022545765 A5 JP2022545765 A5 JP 2022545765A5
Authority
JP
Japan
Prior art keywords
amino acids
sequence
peptide
amino acid
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021577965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545765A (ja
JP7663881B2 (ja
Filing date
Publication date
Priority claimed from EP19382537.9A external-priority patent/EP3756680A1/en
Application filed filed Critical
Publication of JP2022545765A publication Critical patent/JP2022545765A/ja
Publication of JP2022545765A5 publication Critical patent/JP2022545765A5/ja
Application granted granted Critical
Publication of JP7663881B2 publication Critical patent/JP7663881B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021577965A 2019-06-26 2020-06-26 中間径フィラメント由来ペプチドおよびその使用 Active JP7663881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382537.9 2019-06-26
EP19382537.9A EP3756680A1 (en) 2019-06-26 2019-06-26 Intermediate filament-derived peptides and their uses
PCT/EP2020/068052 WO2020260603A1 (en) 2019-06-26 2020-06-26 Intermediate filament-derived peptides and their uses

Publications (3)

Publication Number Publication Date
JP2022545765A JP2022545765A (ja) 2022-10-31
JP2022545765A5 true JP2022545765A5 (enExample) 2023-06-27
JP7663881B2 JP7663881B2 (ja) 2025-04-17

Family

ID=67211651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577965A Active JP7663881B2 (ja) 2019-06-26 2020-06-26 中間径フィラメント由来ペプチドおよびその使用

Country Status (4)

Country Link
US (1) US20220251158A1 (enExample)
EP (2) EP3756680A1 (enExample)
JP (1) JP7663881B2 (enExample)
WO (1) WO2020260603A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4656207A1 (en) 2024-05-30 2025-12-03 Fundació Hospital Universitari Vall Hebron - Institut de Recerca In vitro method for transducing a target cell

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030149A1 (en) * 1996-02-20 1997-08-21 Smithkline Beecham Corporation Novel era
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DE112004002217B4 (de) * 2003-11-19 2017-04-06 Tokyo University Of Science Foundation Proteinbildungskomplex mit einem c-Jun-Protein, Nucleinsäure, codierend denselben und Verfahren unter Verwendung desselben
DE602004019180D1 (de) * 2004-03-16 2009-03-12 Centre Nat Rech Scient Methode zur Identifizierung von unbekannten Proteinen mittels zwei-dimensionaler Auftrennung und Verwendung von Markern
CA2598889A1 (en) * 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
SI22865A (sl) * 2008-09-25 2010-03-31 Univerza@V@Ljubljani Peptid uroaktivin kot aktivator encima urokinaze
WO2017176385A1 (en) * 2016-04-08 2017-10-12 La Jolla Institute For Allergy And Immunology Compositions and methods for diagnosing and treating brain injury
US20210095348A1 (en) * 2017-09-06 2021-04-01 Lawrence Livermore National Security, Llc Methods and systems to perform genetically variant protein analysis, and related marker genetic protein variations and databases

Similar Documents

Publication Publication Date Title
US11229694B2 (en) Vaccine against RSV
US6080398A (en) Truncated gro and KC chemokines having enhanced bioactivity
US10442845B2 (en) Interferon analogs
ES2359616T3 (es) Péptidos citotóxicos modificados por restos voluminosos o lipofílicos.
ES2185595T5 (es) Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
US6235716B1 (en) Multivalent ligands which modulate angiogenesis
JP2008507298A5 (enExample)
JP2023529839A5 (enExample)
JP2023503472A5 (enExample)
IL276359B1 (en) Methods and compositions for inhibiting adam 9 biological activities
AU2008286026B2 (en) Synthetic pulmonary surfactant peptides
WO2009155789A1 (zh) 抑制hiv感染的多肽及其衍生物
ES2349153T3 (es) Inhibidores del virus de la hepatitis c.
US20090155853A1 (en) Non-viral gene delivery complex
CA2190972A1 (en) Compositions of transactivating proteins of human immunodeficiency virus
EP1664099A2 (en) Adenoviral epitopes
US5587457A (en) Neutrophil stimulating peptides
CN101289500A (zh) 病毒感染的长效融合肽抑制剂
CN112029000A (zh) 鸭干扰素α融合蛋白在制备抗鸭1型肝炎病毒的药物中的用途
Raju et al. Substrate analog inhibitors of HIV-1 protease containing phenylnorstatine as a transition state element
CN110357971A (zh) 一种用于紧急预防非洲猪瘟的猪复合干扰素
WO2007054030A1 (en) Polyethylene glycol modifications of thymosin alpha-1
JP2023527048A5 (enExample)
HK40051815A (en) Vaccine against rsv comprising modified f polypeptide
RU2020122291A (ru) Слитый белок, включающий белок il-2 и белок cd80, и его применение